Digital generated image of different variants of virus cells against a black background.

New vaccine technology could protect from future viruses and variants

25 September 2023

Studies of a ‘future-proof’ vaccine candidate have shown that just one antigen can be modified to provide a broadly protective immune response in animals. The studies suggest that a single vaccine with combinations of these antigens – a substance that causes the immune system to produce antibodies against it – could protect against an even greater range of current and future coronaviruses.

Read More
Professor Jonathan Heeney

Cambridge vaccine expert in $42million partnership to develop 'future-proofed' coronavirus vaccines

08 March 2022

Prime Minister Boris Johnson announced that DIOSynVax, a biotech spinout of the University of Cambridge, will receive $42 million (about £32 million) to develop a vaccine candidate that could provide protection against both existing and future variants of SARS-CoV-2 – the virus that causes COVID-19 – as well as other major coronaviruses, including those that cause SARS and MERS.

Read More

Cambridge COVID vaccine in clinical trials

14 December 2021

Safety trials are underway for a vaccine developed by Cambridge researchers that could be used as a booster targeting COVID-19 virus variants and relatives that threaten future coronavirus pandemics.

Read More
Subscribe to DIOSynVax